DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes
- Time in range is a powerful metric for modern diabetes management—but a new survey finds not enough people with diabetes know about it or are using it1
The Global Movement for Timein Range is an educational effort to broaden awareness of time in range and its benefits for people with diabetes and their healthcare providers
- Visit WhenInRange.com to learn more about the movement and how to get involved
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005329/en/
This new, global effort led by
A recent survey found that despite its clinical and quality-of-life benefits, the majority of people with insulin-treated diabetes are not using time in range1—a powerful metric for modern diabetes management—and in many cases, it’s because they don’t know about it.1
Time in range is the percentage of time spent with glucose levels in a target range,2 defined by the T1D Outcomes Program and the International Consensus on Time in Range as 70-180 mg/dL. With time in range, it’s easier to understand how to improve glycemic control and make treatment decisions based on continuous trends in glucose levels instead of relying solely on the three-month average that a traditional A1C test provides.
“This movement is about coming together and giving people with diabetes the tools and resources to help them feel healthier and live the life they want,” said
The survey1 also found:
- The vast majority (83%) of people with insulin-treated diabetes say they feel better when they spend more time in range, but nearly half (47%) say they’re unaware of what time in range is and its advantages as a metric to gauge treatment success
- While the majority (77%) of people with insulin-treated diabetes say they feel healthier when they spend more time in range, more than half (53%) say they’ve never discussed time in range with their healthcare provider
- About two-thirds (68%) of people with insulin-treated diabetes surveyed said they believe it is the responsibility of their healthcare provider to bring new standards of care to their attention
- Three quarters (75%) of people with insulin-treated diabetes agree when their glucose levels are out of range they feel unwell, and the majority (61%) report feeling stressed
- Half (51%) of people with insulin-treated diabetes agree that if they were able to spend more time in range, they’d feel more confident to pursue their dreams or passions
“Healthcare professionals must add time in range as part of their standards of care when it comes to evaluating and treating patients with diabetes—as physicians we can’t get stuck in old ways of thinking,” said Dr.
An effective tool for measuring time in range is a real-time continuous glucose monitoring (CGM) system, an innovative technology that uses a small, wearable sensor and transmitter to measure and send real-time glucose values wirelessly to a smart device or receiver* without the need for fingerpricks.† Real-time CGM technology allows users to see in real-time whether they are in or out of their target range and displays trend arrows to show the speed and direction glucose levels are heading, enabling easier in-the-moment diabetes management decisions.
However, despite the majority (84%) of people with insulin-treated diabetes believing they deserve the most cutting-edge technology available to manage their disease1, some people are still unable to access CGM technology, which will continue to be a barrier in helping all people with diabetes adopt time in range. While significant progress has been made to improve access to CGM, which is covered in some form by 99% of private insurance, Medicare and Medicaid in 40 states, more can be done to broaden coverage as well as existing coverage criteria.
“A key piece of making time in range the standard health metric within diabetes care is increasing access to CGM technology,” said
To learn more about time in range and to access resources for both people with diabetes and healthcare providers, visit WhenInRange.com. Join the conversation on social media at #WhenInRange.
2 The International Consensus on Time in Range recommends a range of 70-180 mg/dL at least 70% of the time. Each individual should consult their healthcare provider.
*For a list of compatible devices, visit www.dexcom.com/compatibility.
† If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.